Bone marrows of non-Hodgkin's lymphoma patients with a bcl-2 translocation can be purged of polymerase chain reaction-detectable lymphoma cells using monoclonal antibodies and immunomagnetic bead depletion.

Using the extremely sensitive technique of polymerase chain reaction (PCR) to detect the bcl-2 translocation, only 50% of bone marrows could be purged of PCR-detectable lymphoma cells using a cocktail of three anti-B-cell monoclonal antibodies (MoAbs) and complement-mediated lysis. This observation is of clinical importance because those patients whose reinfused marrows harbored residual lymphoma cells showed a significantly increased incidence of relapse. To improve purging, we used PCR detection of the bcl-2 translocation to compare the efficiency of complement-mediated lysis with immunomagnetic bead depletion. Using either a three or a four MoAb cocktail followed by immunomagnetic bead depletion, all PCR-detectable cells were purged after three cycles of treatment. In these same patient samples, treatment with three MoAbs and complement purged only 11 of the 25 (44%) samples. The addition of a fourth MoAb followed by complement lysis purged the marrows of only an additional five patients. Immunomagnetic bead depletion was specific because there was no loss of committed myeloid progenitor cells. The above results suggest that immunomagnetic bead depletion of the harvested marrow will likely be superior to our previous method of purging and the lack of nonspecific toxicity to myeloid progenitor cells predicts that it will not impair engraftment. This methodology will now be used to determine whether the reinfusion of lymphoma free marrow affects the incidence of relapse after autologous bone marrow transplantation.

[1]  J. Ritz,et al.  In vitro regulation of human hematopoiesis by natural killer cells: analysis at a clonal level. , 1987, Blood.

[2]  T. Borsós,et al.  Effect of inhibiting DNA, RNA, and protein synthesis of tumor cells on their susceptibility to killing by antibody and complement. , 1977, Cancer Research.

[3]  M. Oken,et al.  bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. , 1989, The New England journal of medicine.

[4]  M. Cleary,et al.  Use of the polymerase chain reaction to monitor the effectiveness of ex vivo tumor cell purging. , 1991, Blood.

[5]  J. Ultmann,et al.  Bone marrow involvement in non‐Hodgkin's lymphoma. Implications for staging and therapy , 1976, Cancer.

[6]  J. Kersey,et al.  Marrow purging in autologous bone marrow transplantation for T-lineage acute lymphoblastic leukemia: efficacy of ex vivo treatment with immunotoxins and 4-hydroperoxycyclophosphamide against fresh leukemic marrow progenitor cells. , 1987, Blood.

[7]  K. Anderson,et al.  Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. , 1987, The New England journal of medicine.

[8]  L. Nadler,et al.  A monoclonal antibody defining a lymphoma-associated antigen in man. , 1980, Journal of immunology.

[9]  J. Ritz,et al.  A unique cell surface antigen identifying lymphoid malignancies of B cell origin. , 1981, The Journal of clinical investigation.

[10]  J. Gribben,et al.  All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. , 1991, Blood.

[11]  A. Gee,et al.  Evidence for an anticomplementary factor associated with human bone marrow cells. , 1985, Journal of the National Cancer Institute.

[12]  J. Gribben,et al.  Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. , 1991, The New England journal of medicine.

[13]  W. Velasquez,et al.  The gene located at chromosome 18 band q21 is rearranged in uncultured diffuse lymphomas as well as follicular lymphomas. , 1987, Blood.

[14]  M. Cleary,et al.  Detection of chromosomal translocation t(14;18) within the minor cluster region of bcl-2 by polymerase chain reaction and direct genomic sequencing of the enzymatically amplified DNA in follicular lymphomas. , 1989, Blood.

[15]  T. Borsós,et al.  Lysis of hapten-labeled cells by anti-hapten IgG and complement: effect of cell surface hapten density. , 1982, Journal of immunology.

[16]  R. R. Howe,et al.  Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. , 1982, The New England journal of medicine.

[17]  B. Yeap,et al.  Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  E J Freireich,et al.  Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. , 1987, Science.

[19]  S. Korsmeyer,et al.  Thermostable DNA polymerase chain amplification of t(14;18) chromosome breakpoints and detection of minimal residual disease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[20]  C. Bloomfield,et al.  Incidence, cytology, and histopathology of non‐Hodgkin's lymphomas in the bone marrow , 1974, Cancer.

[21]  C. Bloomfield,et al.  Autologous bone marrow transplantation in non-Hodgkin's lymphoma: monoclonal antibodies plus complement for ex vivo marrow treatment. , 1988, The American journal of medicine.

[22]  A. Freedman,et al.  B5, a new B cell-restricted activation antigen. , 1985, Journal of immunology.

[23]  G. Marti,et al.  B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. , 1983, Journal of immunology.

[24]  T. Borsós,et al.  Identification of lipids associated with the ability of tumor cells to resist humoral immune attack. , 1978, Journal of immunology.